Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

KRON - Kronos Bio, Inc.

IEX Last Trade
0.9221
0.002   0.228%

Share volume: 32,203
Last Updated: Thu 26 Dec 2024 08:28:38 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): -0.11%

PREVIOUS CLOSE
CHG
CHG%
$0.92
0.00
0.23%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
-0.01%
1 Month
9.82%
3 Months
-0.50%
6 Months
-0.01%
1 Year
-25.20%
2 Year
-38.32%
Key data
Stock price
$0.92
P/E Ratio 
0.00
DAY RANGE
$0.90 - $0.93
EPS 
$0.00
52 WEEK RANGE
$0.76 - $1.60
52 WEEK CHANGE
-$23.40
MARKET CAP 
63.309 M
YIELD 
N/A
SHARES OUTSTANDING 
60.295 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/14/2024
BETA 
1.17
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$208,193
AVERAGE 30 VOLUME 
$376,024
Company detail
CEO: Norbert W. Bischofberger
Region: US
Website: kronosbio.com
Employees: 100
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. Its lead product candidate is entospletinib (ENTO), an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company was incorporated in 2017 and is headquartered in San Mateo, California.

Recent news